A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

At the urging of the group Do No Harm, a 2-1 court panel revisted a decision it issued last year holding the organization ...

A federal appeals court revived a lawsuit on Friday challenging Pfizer Inc.‘s fellowship program aimed at building a diverse ...

Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

Valued at a market cap of $152.2 billion, Pfizer Inc. (PFE) is a global biopharmaceutical company dedicated to advancing ...

Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate ...

Alzheimer’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...

Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC. Click here to find out why I ...